---
title: "FibroGen Rebrands as Kyntra Bio"
description: "FibroGen Inc. has rebranded as Kyntra Bio, focusing on novel therapies for oncology and rare diseases. The company will now trade on Nasdaq under the symbol \"KYNB.\""
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/271788320.md"
published_at: "2026-01-07T12:30:17.000Z"
---

# FibroGen Rebrands as Kyntra Bio

> FibroGen Inc. has rebranded as Kyntra Bio, focusing on novel therapies for oncology and rare diseases. The company will now trade on Nasdaq under the symbol "KYNB."

FibroGen Inc. has announced a rebranding to Kyntra Bio, reflecting a new focus on developing novel therapies for oncology and rare diseases. The company will now trade on Nasdaq under the symbol “KYNB.” Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. FibroGen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9621142-en) on January 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [FGEN.US - Fibrogen](https://longbridge.com/en/quote/FGEN.US.md)
- [KYNB.US - Kyntra Bio](https://longbridge.com/en/quote/KYNB.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| FibroGen Inc. Unveils Corporate Presentation Highlighting Strategic Sale, Cash Runway Extension, and Advances in Prostate Cancer Treatment | FibroGen Inc. has announced a strategic sale of FibroGen China to AstraZeneca for $220 million, extending its cash runwa | [Link](https://longbridge.com/en/news/257782710.md) |
| FibroGen Completes $220 Million Sale of Chinese Subsidiary to AstraZeneca, Extending Cash Runway to 2028 | FibroGen, Inc. has completed the sale of its Chinese subsidiary to AstraZeneca for approximately $220 million, enhancing | [Link](https://longbridge.com/en/news/255599340.md) |
| FibroGen posts Q3 net income of $200.6 mln after sale of China operations | FibroGen reported a Q3 net income of $200.6 million, primarily due to the sale of its China operations to AstraZeneca fo | [Link](https://longbridge.com/en/news/265212615.md) |
| FibroGen’s Strategic Moves and Financial Highlights | FibroGen (FGEN) reported its Q3 earnings, highlighting strategic and financial developments. The company sold its China  | [Link](https://longbridge.com/en/news/265261078.md) |
| Hold Rating on FibroGen’s FG-3246 Amid Competitive Prostate Cancer Treatment Landscape and Upcoming Trial Data | Andy Hsieh maintains a Hold rating on FibroGen’s FG-3246 due to competitive pressures in the prostate cancer treatment l | [Link](https://longbridge.com/en/news/263674229.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.